Long-Term Hair Loss Associated With Brentuximab Vedotin–Containing Chemotherapy And Its Psychosocial Impact: A Retrospective Observational Study Conducted At The Royal Marsden Hospital
May 2026
in “
Journal of Clinical Oncology
”
Studysummary This study found that nearly 40% of Hodgkin’s Lymphoma patients who received Brentuximab Vedotin with AVD chemotherapy experienced persistent alopecia more than two years after treatment, leading to significant psychosocial consequences such as reduced self-confidence and emotional distress.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on ascopubs.org →